María T Prieto-Sánchez1, María Ruiz-Palacios2, José E Blanco-Carnero1, Ana Pagan2, Christian Hellmuth3, Olaf Uhl3, Wolfgang Peissner3, Antonio J Ruiz-Alcaraz4, Juan J Parrilla1, Berthold Koletzko3, Elvira Larqué5. 1. Obstetrics and Gynecology Service, Virgen de la Arrixaca Clinical Hospital, University of Murcia, Spain. 2. Department of Physiology, Faculty of Biology, Campus Mare Nostrum, University of Murcia, Spain. 3. Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University of Munich, München, Germany. 4. Department of Biochemistry, Molecular Biology B and Immunology, University of Murcia, Spain. 5. Department of Physiology, Faculty of Biology, Campus Mare Nostrum, University of Murcia, Spain. Electronic address: elvirada@um.es.
Abstract
BACKGROUND & AIMS: Maternal-fetal transfer of docosahexaenoic acid (DHA) is impaired by gestational diabetes mellitus (GDM), but the underlying mechanisms are still unknown. MFSD2a was recently recognized as a lyso-phospholipid (lyso-PL) transporter that facilitates DHA accretion in brain. The role of this transporter in placenta is uncertain. We evaluated effects of GDM and its treatment (diet or insulin) on phospholipid species, fatty acid profile in women, cord blood and placental fatty acid carriers. METHODS: Prospective observational study of pregnant women recruited in the third trimester (25 controls, 23 GDM-diet, 20 GDM-insulin). Fetal ultrasound was performed at gestational week 38. At delivery, maternal and neonatal anthropometry was performed, and fatty acids in total lipids and phospholipid species were analyzed in placenta, maternal and venous cord blood. Western-blot analyses were performed for placental fatty acid carriers. RESULTS: Fetal abdominal circumference z-score at 38 weeks tended to higher values in GDM (P = 0.071), pointing toward higher fetal fat accretion in these babies. DHA percentage in cord serum total lipids (P = 0.029) and lyso-PL (P = 0.169) were reduced in GDM. Placental MFSD2a was reduced in both GDM groups and was positively correlated to DHA values in cord serum total lipids (r = 0.388, P = 0.003). Among established placental lipid carriers, only FATP4 was correlated to DHA concentration in placental lyso-PL. In all compartments, DHA percentage was inversely correlated to fetal abdominal circumference. CONCLUSIONS: In offspring of women with GDM treated either with diet or insulin, higher fetal fat accretion and lower placental MFSD2a contribute to reduce DHA availability. Lyso-PL appear to contribute to materno-fetal DHA transport.
BACKGROUND & AIMS: Maternal-fetal transfer of docosahexaenoic acid (DHA) is impaired by gestational diabetes mellitus (GDM), but the underlying mechanisms are still unknown. MFSD2a was recently recognized as a lyso-phospholipid (lyso-PL) transporter that facilitates DHA accretion in brain. The role of this transporter in placenta is uncertain. We evaluated effects of GDM and its treatment (diet or insulin) on phospholipid species, fatty acid profile in women, cord blood and placental fatty acid carriers. METHODS: Prospective observational study of pregnant women recruited in the third trimester (25 controls, 23 GDM-diet, 20 GDM-insulin). Fetal ultrasound was performed at gestational week 38. At delivery, maternal and neonatal anthropometry was performed, and fatty acids in total lipids and phospholipid species were analyzed in placenta, maternal and venous cord blood. Western-blot analyses were performed for placental fatty acid carriers. RESULTS: Fetal abdominal circumference z-score at 38 weeks tended to higher values in GDM (P = 0.071), pointing toward higher fetal fat accretion in these babies. DHA percentage in cord serum total lipids (P = 0.029) and lyso-PL (P = 0.169) were reduced in GDM. Placental MFSD2a was reduced in both GDM groups and was positively correlated to DHA values in cord serum total lipids (r = 0.388, P = 0.003). Among established placental lipid carriers, only FATP4 was correlated to DHA concentration in placental lyso-PL. In all compartments, DHA percentage was inversely correlated to fetal abdominal circumference. CONCLUSIONS: In offspring of women with GDM treated either with diet or insulin, higher fetal fat accretion and lower placental MFSD2a contribute to reduce DHA availability. Lyso-PL appear to contribute to materno-fetal DHA transport.
Authors: Alejandra Abascal-Saiz; Eva Fuente-Luelmo; María Haro; María de la Calle; María P Ramos-Álvarez; Germán Perdomo; José L Bartha Journal: Reprod Sci Date: 2020-11-10 Impact factor: 3.060
Authors: Christian Hellmuth; Olaf Uhl; Marie Standl; Hans Demmelmair; Joachim Heinrich; Berthold Koletzko; Elisabeth Thiering Journal: Obes Facts Date: 2017-04-05 Impact factor: 3.942
Authors: Samuel Furse; Sara L White; Claire L Meek; Benjamin Jenkins; Clive J Petry; Matias C Vieira; Susan E Ozanne; David B Dunger; Lucilla Poston; Albert Koulman Journal: Mol Omics Date: 2019-12-02
Authors: Birgit Hirschmugl; Sarah Crozier; Nina Matthews; Eva Kitzinger; Ingeborg Klymiuk; Hazel M Inskip; Nicholas C Harvey; Cyrus Cooper; Colin P Sibley; Jocelyn Glazier; Christian Wadsack; Keith M Godfrey; Gernot Desoye; Rohan M Lewis Journal: Int J Obes (Lond) Date: 2018-06-13 Impact factor: 5.095